Combination therapy plus ablation for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug combination (AG and nimotuzumab) followed by a procedure called irreversible electroporation (IRE) to treat locally advanced pancreatic cancer that hasn't spread. It aims to see if this approach can help patients whose cancer can't be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has been confirmed by a biopsy and is locally advanced (has not spread to other organs).
- You have not had chemotherapy or other cancer treatments before.
- Your cancer can be measured on a scan (CT or MRI).
- You are in reasonably good health, with adequate blood counts, liver and kidney function, and can care for yourself (ECOG 0-2).
- If you are able to have children, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
Hear when a new Pancreatic Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.